Our products

Sacubitril/Valsartan Complex



Reference product


Polymorphic form


Therapeutic Area

Cardiovascular system



EU DMF readiness

US DMF readiness


Polpharma API characteristics:

  • Crystalline form with appropriate ratio of Sacubitril/Valsartan, same as the originator
  • Own Sacubitril technology under development to secure backward integration and control of impurity level
  • Sustainable and reliable assay results
  • Amorphous form can be considered upon request (laboratory samples available)
  • Technical support available on request

Drug description:

Sacubitril and Valsartan is a fixed dose combination acts as an anti-hypertensive and cardiovascular agent.
It is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure and reduced ejection fraction.
It is formulated as film coated tablets for oral route of administration.

Mechanism of action:

Valsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland1. Sacubitril inhibits neprilysin, a neutral endopeptidase that would typically cleave natriuretic peptides such as atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and c-type natriuretic peptide (CNP). ANP and BNP are released under atrial and ventricle stress, which activate downstream receptors leading to vasodilation, natriuresis and diuresis. Under normal conditions, neprilysin breaks down other vasodilating peptides and also vasoconstrictors such as angiotensin I and II, endothelin-1 and peptide amyloid beta-protein. Inhibition of neprilysin therefore leads to reduced breakdown and increased concentration of endogenous natriuretic peptides in addition to increased levels of vasoconstricting hormones such as angiotensin II.

The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products with PIPELINE & EARLY DEVELOPMENT STATUS under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP right.